(A) RNA-seq analysis confirms the effect of NSC/nutlin-3 co-treatment on p53 activation. LNCaP cells were treated with DMSO, nutlin-3 (5 µM), NSC (NSC207895; 10 µM), or combination of nutlin-3 and NSC for 30 hours. Total RNAs were extracted and subjected to Bioanalyzer for quality control followed by RNA-seq analysis (Illumina 4000; 30M reads; Columbia genome center). Normalized expression levels (FPKM) of known p53 targets p21, PUMA, MDM2, PIG3, GADD45a, and BAX were analyzed and relative expression levels were calculated in comparison to DMSO-treated sample. (B) Expression of AR signaling targets were enriched in DMSOtreated but not NSC/nutlin-3 co-treated LNCaP cells. A list of 83 androgen receptor signaling target genes (Androgen Receptor Signaling Targets PCR Array; Qiagen; supplemental excel file) was analyzed using Gene Set Enrichment Analysis (http://software.broadinstitute.org/ gsea/index.jsp; GSEA) to compare their expression levels in DMSO-treated or NSC/nutlin-3 co-treated RNA-seq dataset. Majority of these genes were found to be enriched in DMSO-treated samples, suggesting their expression were repressed in NSC/nutlin-3 co-treated sample.
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